ArticleBiomedical reports2016
Urinary volatile organic compounds as potential biomarkers for renal cell carcinoma.
Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Urinary and cellular volatile organic compounds as biomarkers for urological cancers: a systematic review of GC-MS-based volatolomics.Metabolomics : Official journal of the Metabolomic Society · 2026Pooled it
- Urinary volatile organic compounds as potential non-invasive markers for childhood obesity.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Colorectal Cancer Detection Through Sweat Volatilome Using an Electronic Nose System and GC-MS Analysis.Cancers · 2025Article
- Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Detection and Validation of Organic Metabolites in Urine for Clear Cell Renal Cell Carcinoma Diagnosis.Metabolites · 2024Article
- Urinary cancer detection by the target urine volatile organic compounds biosensor platform.Scientific reports · 2024Article
- Global Urinary Volatolomics with (GC×)GC-TOF-MS.Analytical chemistry · 2023Article
- Article
- Investigating the effects of storage conditions on urinary volatilomes for their reliability in disease diagnosis.American journal of clinical and experimental urology · 2023Article
- The untargeted urine volatilome for biomedical applications: methodology and volatilome database.Biological procedures online · 2022Review
- Mapping of Urinary Volatile Organic Compounds by a Rapid Analytical Method Using Gas Chromatography Coupled to Ion Mobility Spectrometry (GC-IMS).Metabolites · 2022Article
- Volatilomics: An Emerging and Promising Avenue for the Detection of Potential Prostate Cancer Biomarkers.Cancers · 2022Review
- Volatolomics in healthcare and its advanced detection technology.Nano research · 2022Review
- Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer.Cancers · 2021Article
- Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics.Metabolites · 2021Article
- Analysis of urinary VOCs using mass spectrometric methods to diagnose cancer: A review.Clinical mass spectrometry (Del Mar, Calif.) · 2020Review
- Volatilomics Reveals Potential Biomarkers for Identification of Renal Cell Carcinoma: An In Vitro Approach.Metabolites · 2020Article
- Analysis of volatile organic compounds released from SW480 colorectal cancer cells and the blood of tumor-bearing mice.Translational cancer research · 2019Article
- Detection and analysis of endogenous polar volatile organic compounds (PVOCs) in urine for human exposome research.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2019Article
- Urinary metabolites for urological cancer detection: a review on the application of volatile organic compounds for cancers.American journal of clinical and experimental urology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is no adequate, sensitive, reproducible, specific and noninvasive biomarker that can reliably be used to detect renal cell carcinoma (RCC). Previous studies have elucidated the urinary non-volatile metabolic profile of RCC. However, whether urinary volatile organic compound (VOC) profiles are able to identify RCC remains to be elucidated. In the present study, urine was collected from 22 patients with RCC and 25 healthy subjects. Principal component analysis and orthogonal partial least square discriminant analysis were used to compare the data of patients and healthy subjects, and preoperative and postoperative patients undergoing radical nephrectomy. In total, 11 VOC biomarkers were elevated in the RCC patients compared to the healthy subjects, which were phenol; decanal; 1,6-dioxacyclododecane-7,12-dione; 1-bromo-1-(3-methyl-1-pentenylidene)-2,2,3,3-tetramethyl-cyclopropane; nonanal; 3-ethyl-3-methylheptane; isolongifolene-5-ol; 2,5-cyclohexadiene-1,4-dione, 2,6-bis(1,1-dimethylethyl); tetradecane; aniline; and 2,6,10,14-tetramethyl-pentadecane. Three biomarkers were decreased in RCC patients: styrene, 4-heptanone and dimethylsilanediol. In preoperative patients, 2-ethyl-1-hexanol and cyclohexanone were elevated, while 6-t-butyl-2,2,9,9-tetramethyl-3,5-decadien-7-yne were decreased when compared to postoperative patients. Compared with the healthy subjects, RCC has a unique VOC profile, suggesting that VOC profiles may be a useful diagnostic assay for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.